Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)

Tait D. Shanafelt, Sameer A. Parikh, Peter A. Noseworthy, Valentin Goede, Kari G. Chaffee, Jasmin Bahlo, Timothy G. Call, Susan M. Schwager, Wei Ding, Barbara Eichhorst, Kirsten Fischer, Jose F. Leis, Asher Alban Chanan-Khan, Michael Hallek, Susan L. Slager, Neil E. Kay

Research output: Contribution to journalArticlepeer-review

52 Scopus citations


Although preliminary data suggests that ibrutinib may increase risk of atrial fibrillation (AF), the incidence of AF in a general cohort of chronic lymphocytic leukemia (CLL) patients is unknown. We evaluated the prevalence of AF at CLL diagnosis and incidence of AF during follow-up in 2444 patients with newly diagnosed CLL. A prior history of AF was present at CLL diagnosis in 148 (6.1%). Among the 2292 patients without history of AF, 139 (6.1%) developed incident AF during follow-up (incidence approximately 1%/year). Older age (p <.0001), male sex (p =.01), valvular heart disease (p =.001), and hypertension (p =.04) were associated with risk of incident AF on multivariate analysis. A predictive model for developing incident AF constructed from these factors stratified patients into 4 groups with 10-year rates of incident AF ranging from 4% to 33% (p <.0001). This information provides context for interpreting rates of AF in CLL patients treated with novel therapies.

Original languageEnglish (US)
Pages (from-to)1630-1639
Number of pages10
JournalLeukemia and Lymphoma
Issue number7
StatePublished - Jul 3 2017


  • Chronic lymphocytic leukemia
  • atrial fibrillation
  • ibrutinib
  • risk factors

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)'. Together they form a unique fingerprint.

Cite this